scout

Natalie S. Callander, MD, University of Washington Carbone Cancer Center

Articles by Natalie S. Callander, MD, University of Washington Carbone Cancer Center

Experts on MM

Multiple Myeloma: Unmet Needs and Future Directions in Care

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.

Experts on MM

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Experts on MM

Bispecifics in Multiple Myeloma: Dosing and Transition of Care

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Experts on MM

Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.

Expert on MM

Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.

Experts on MM

Factors in Selecting Therapy at First Relapse in Multiple Myeloma

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.

Experts on MM

Patient Scenario: Treatment Options in MM at First Relapse

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.

Experts on MM

Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.

Expert on MM

Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.

Experts on MM

Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.

Expert on MM

NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.

Latest Updated Articles